Screener
United Therapeutics UTHR EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by United Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: United Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001082554-26-000027
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Income tax expense | (39.7) | (98.9) | (83.1) | (200.2) |
| Net income | $333.0 | $309.5 | $607.9 | $631.7 |
| Net income per common share: | ||||
| Basic | $7.82 | $6.86 | $14.14 | $14.04 |
| Diluted | $7.27 | $6.41 | $13.07 | $13.02 |
| Weighted average number of common shares outstanding: | ||||
| Basic | 42.6 | 45.1 | 43.0 | 45.0 |
| Diluted | 45.8 | 48.3 | 46.5 | 48.5 |
Item 1. Consolidated Financial Statements
FAQ
- What is United Therapeutics's EPS (basic)?
- United Therapeutics (UTHR) reported EPS (basic) of $7.82 in Q2 2026.
- How has United Therapeutics's EPS (basic) changed year-over-year?
- United Therapeutics's EPS (basic) increased by 14.0% year-over-year, from $6.86 to $7.82.
- What is the long-term trend for United Therapeutics's EPS (basic)?
- Over 4 years (2021 to 2025), United Therapeutics's EPS (basic) has grown at a 29.9% compound annual growth rate (CAGR), from $10.58 to $30.14.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about United Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude